SCI时时刷

search
+
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
Competing interests DH: None. SL: None. SAW: None. MYK: reports research c...
The expanding CML treatment landscape: an introspective commentary
The article by Abdelmagid and co-authors on real-world experience with ponatinib that accompanies this ed...
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
FLT3 is the most frequently mutated gene in acute myeloid leukemia (AML), with FLT3 internal tandem duplication (ITD) muta...
Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma
Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma
Biallelic TP53 inactivation is the most important high-risk factor associated with poor survival in multiple myeloma. Clas...
Zanubrutinib: past, present, and future
Zanubrutinib: past, present, and future
In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances in the treatment of patients w...
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
Variability in the molecular response to frontline tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia may...
Prospective evaluation of genome sequencing to compare conventional cytogenetics in acute myeloid leukemia
Prospective evaluation of genome sequencing to compare conventional cytogenetics in acute myeloid leukemia
Acute myeloid leukemia (AML) can be classified into multiple genetic subtypes based on recurrent pathogen...
Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis
Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis
Rituximab-based chemo-immunotherapy is currently the standard first-line treatment for Waldenstrom macroglobulinaemia (WM)...
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia
The deregulation of BCL2 family proteins plays a crucial role in leukemia development. Therefore, pharmacological inhibiti...
Clinical characteristics, genomic profiling and outcomes of single system multifocal Langerhans cell histiocytosis in adults with bone involvement
Clinical characteristics, genomic profiling and outcomes of single system multifocal Langerhans cell histiocytosis in adults with bone involvement
Langerhans cell histiocytosis (LCH) is a rare, heterogeneous histiocytic disease derived from the misguid...
Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease
Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease
Prolonged viral shedding (PVS) results from a failure of viral eradication. Before the emergence of SARS-...
Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
Testing for measurable residual disease (MRD) in persons with plasma cell myeloma (PCM) after therapy cor...
Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival
Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival
Multiple myeloma (MM) is a rarely curable plasma cell malignancy of the bone marrow (BM) that provides a ...
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) patients as part of ...
Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study
Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study
Molecular techniques are the gold standard method for the diagnosis of AML with mutated nucleophosmin gen...
Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
Gemtuzumab ozogamicin (GO) is a CD33-directed antibody-drug conjugate approved for the treatment of newly diagnosed (ND) a...
A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
Histological transformation of marginal zone lymphoma (tMZL) into diffuse large B-cell lymphoma is associated with poor ou...
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, CanadaArleigh McCurdy & Alissa VisramJuravinski C...
Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance
Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous l...
Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
PET/CT is used to evaluate relapsed/refractory non-Hodgkin lymphoma (NHL) prior to chimeric antigen receptor T-cell (CAR-T...
Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
Allogeneic stem cell transplant (allo SCT) for multiple myeloma (MM) is potentially curative in some, while toxic in many ...
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study
The real-world patient-level data were derived from two prospective cohort studies. The first SMC-LCS (2008–2011, NCT#0082...
The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain
The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain
MYD88 is the key signaling adaptor-protein for Toll-like and interleukin-1 receptors. A somatic L265P mutation within the ...
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma
T-lymphocytes are prevalent in the tumor microenvironment of follicular lymphoma (FL). However, the phenotype of T-cells m...
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
We surveyed the performance of ponatinib, as salvage therapy, in a real-world setting of chronic phase chronic myeloid leu...
Multiomics of three hematological malignancies in a patient reveal their origin from clonal hematopoietic stem cells
Multiomics of three hematological malignancies in a patient reveal their origin from clonal hematopoietic stem cells
Multiple hematological malignancies can occur simultaneously or sequentially in a single patient. They ar...
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
The continuous treatment model of Bruton tyrosine kinase inhibitors (BTKi) in chronic lymphocytic leukemi...
Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis
Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare neoplasm derived from plasmacytoid dendrit...
Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification
Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification
Myelodysplastic syndromes (MDS) have varied prognoses and require a risk-adapted treatment strategy for treatment optimiza...
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted t...
阅读更多
format_indent_increase